Phase I-II study of a Farnesyl Transferase Inhibitor (FTI), SCH66336, in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML).

Ravoet, C; Mineur, P.; Robin, V.; Debusscher, L.; Bosly, André; André, Marc; El Housni, H.; Soree, A; Martiat, P.

Phase I-II study of a Farnesyl Transferase Inhibitor (FTI), SCH66336, in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML).

Ravoet, C

;

Mineur, P.

;

Robin, V.

;

Debusscher, L.

;

Martiat, P.

;et.al.

(2002) 44th Annual Meeting of the American-Society-of-Hematology — Location: PHILADELPHIA(Pennsylvania) (6.December.2002)

Files

No attached file found for this publication.

Details

Authors

Ravoet, C
Author
Mineur, P.
Author
Robin, V.
Author
Debusscher, L.
Author
Bosly, AndréUCLouvain
Author
Martiat, P.
Author

Affiliations

UCLouvainAutre

Citations

APA
Chicago
FWB

Ravoet, C., Mineur, P., Robin, V., Debusscher, L., Bosly, A., André, M., El Housni, H., Soree, A., & Martiat, P. (2002). Phase I-II study of a Farnesyl Transferase Inhibitor (FTI), SCH66336, in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML). Blood, 100(11), 794A. https://hdl.handle.net/2078.5/67119 (Original work published 2002)